|
Title
|
|
|
|
Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Inhibition of platelet activation may reduce vaso-occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg <6 months; 0.2 mg/kg >= 6 to <24 months). All patients had measurable ticagrelor plasma concentrations. Ticagrelor and active metabolite (AR-C124910XX) exposure were comparable across all groups (<6 months, >= 6 to <12 months and >= 12 to <24 months). Ticagrelor was well tolerated. Palatability was generally acceptable. These data will be used to enable dose selection for further investigations of ticagrelor efficacy and safety in children with SCD. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Pediatric Blood and Cancer. - -
| |
|
Publication
|
|
|
|
Hoboken
:
Wiley
,
2021
| |
|
ISSN
|
|
|
|
1545-5009
| |
|
DOI
|
|
|
|
10.1002/PBC.28977
| |
|
Volume/pages
|
|
|
|
68
:5
(2021)
, 5 p.
| |
|
Article Reference
|
|
|
|
e28977
| |
|
ISI
|
|
|
|
000621421500001
| |
|
Pubmed ID
|
|
|
|
33629819
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|